• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分析 71 例 HIV 阴性血管滤泡性淋巴结增生症患者的临床特征及预后因素:低蛋白血症是一个不利的预后因素,应适当治疗。

Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.

机构信息

Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No 1 Jianshe St., Erqi District, Zhengzhou, 450052, China.

出版信息

J Cancer Res Clin Oncol. 2018 Jul;144(7):1265-1277. doi: 10.1007/s00432-018-2647-z. Epub 2018 May 7.

DOI:10.1007/s00432-018-2647-z
PMID:29736622
Abstract

PURPOSE

HIV negative Castleman's disease has been reported as a group of poorly understood lymphoproliferative disorder, and we want to explore the clinical feature and prognosis factors of CD.

METHODS

We retrospectively collected the clinical information of 71 CD patients without HIV infection diagnosed in the first affiliated hospital of Zhengzhou university.

RESULTS

Different clinical classifications, including 35 patients (49.30%) with unicentric Castleman disease and 36 (50.7%) with multicentric Castleman disease, has their specific features compared with each other and unfavorable risk factors calculated by the univariate analysis. As for all of CD patients without HIV infection, there were 7 significant risk factors identified by the results of log-rank test, including clinical complaint, edema (hydrothorax, ascites, pelvic effusion), fatigue, anemia, hypoproteinemia and elevated serum β2-MG. Then, we created a Cox regression model of these clinical and statistic significant factors which indicated hypoproteinemia was an independent poor prognosis factors of CD in both univariate and multivariate analysis.

CONCLUSIONS

Our study emphasized the distinction of clinical characteristics between UCD and MCD and the importance of different poor risk factors of different clinical classifications which may directed more precise and appropriate treatment strategy.

摘要

目的

HIV 阴性血管滤泡性淋巴结增生症(Castleman's disease,CD)被报道为一组尚未完全阐明的淋巴组织增生性疾病,我们希望探讨无 HIV 感染的 CD 患者的临床特征和预后因素。

方法

我们回顾性收集了郑州大学第一附属医院诊断的 71 例无 HIV 感染的 CD 患者的临床资料。

结果

不同的临床分类,包括 35 例(49.30%)局灶性 Castleman 病和 36 例(50.7%)多中心 Castleman 病,与各自的特征和单因素分析计算的不利风险因素有关。对于所有无 HIV 感染的 CD 患者,通过对数秩检验结果确定了 7 个显著的风险因素,包括临床症状、水肿(胸腔积液、腹水、盆腔积液)、疲劳、贫血、低蛋白血症和血清β2-MG 升高。然后,我们根据这些临床和统计学显著的因素建立了 Cox 回归模型,结果表明低蛋白血症是单因素和多因素分析中 CD 的独立不良预后因素。

结论

我们的研究强调了 UCD 和 MCD 之间的临床特征区别,以及不同临床分类的不同不良风险因素的重要性,这可能有助于制定更精确和合适的治疗策略。

相似文献

1
Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman's disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately.分析 71 例 HIV 阴性血管滤泡性淋巴结增生症患者的临床特征及预后因素:低蛋白血症是一个不利的预后因素,应适当治疗。
J Cancer Res Clin Oncol. 2018 Jul;144(7):1265-1277. doi: 10.1007/s00432-018-2647-z. Epub 2018 May 7.
2
Idiopathic multicentric Castleman's disease: a systematic literature review.特发性多中心Castleman病:一项系统的文献综述
Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17.
3
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
4
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
5
Multicentric Castleman's disease in HIV infection: a systematic review of the literature.HIV感染中的多中心Castleman病:文献系统综述
AIDS Rev. 2008 Jan-Mar;10(1):25-35.
6
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
7
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
8
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].[容量与健康结果:来自系统评价和意大利医院数据评估的证据]
Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100.

引用本文的文献

1
Spatial transcriptomics study of Castleman disease.Castleman病的空间转录组学研究。
J Transl Med. 2025 Apr 19;23(1):459. doi: 10.1186/s12967-025-06456-9.
2
F-FDG PET/CT metabolic parameters are correlated with clinical features and valuable in clinical stratification management in patients of castleman disease.F-FDG PET/CT代谢参数与Castleman病患者的临床特征相关,对其临床分层管理具有重要价值。
Cancer Imaging. 2025 Feb 12;25(1):12. doi: 10.1186/s40644-025-00833-9.
3
Prediction of tuberculosis-specific mortality for older adult patients with pulmonary tuberculosis.

本文引用的文献

1
Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.HIV和HHV-8阴性的Castleman病的临床和病理特征
Blood. 2017 Mar 23;129(12):1658-1668. doi: 10.1182/blood-2016-11-748855. Epub 2017 Jan 18.
2
Idiopathic multicentric Castleman's disease: a systematic literature review.特发性多中心Castleman病:一项系统的文献综述
Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17.
3
Bone marrow manifestations in multicentric Castleman disease.多中心性Castleman病的骨髓表现
老年肺结核患者结核病特异性死亡率的预测
Front Public Health. 2025 Jan 15;12:1515867. doi: 10.3389/fpubh.2024.1515867. eCollection 2024.
4
The clinical picture of Castleman disease: a systematic review and meta-analysis.卡斯特曼病的临床特征:一项系统评价和荟萃分析。
Blood Adv. 2024 Sep 24;8(18):4924-4935. doi: 10.1182/bloodadvances.2024013548.
5
Human Herpesvirus-8 (HHV-8)-Positive Human Immunodeficiency Virus (HIV)-Negative Multicentric Castleman Disease With a Fulminant Course.人类疱疹病毒8型(HHV-8)阳性、人类免疫缺陷病毒(HIV)阴性且病程凶险的多中心Castleman病
Cureus. 2024 Feb 17;16(2):e54350. doi: 10.7759/cureus.54350. eCollection 2024 Feb.
6
Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up.Castleman病的临床特征与预后:一项对428例患者进行15年随访的多中心联合研究
Am J Cancer Res. 2022 Sep 15;12(9):4227-4240. eCollection 2022.
7
Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.60 例人类免疫缺陷病毒阴性血管滤泡性淋巴结增生症患者的临床和分子特征。
Front Immunol. 2022 May 17;13:899073. doi: 10.3389/fimmu.2022.899073. eCollection 2022.
8
Comprehensive analysis of 65 patients with Castleman disease in a single center in China.中国单中心 65 例血管滤泡性淋巴结增生症患者的综合分析。
Sci Rep. 2022 May 24;12(1):8694. doi: 10.1038/s41598-022-12797-y.
9
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.国际循证共识性单中心Castleman 病诊断与治疗指南。
Blood Adv. 2020 Dec 8;4(23):6039-6050. doi: 10.1182/bloodadvances.2020003334.
Br J Haematol. 2016 Mar;172(6):923-9. doi: 10.1111/bjh.13919. Epub 2016 Jan 28.
4
Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.一项关于西妥昔单抗(抗 IL-6 单克隆抗体)治疗多发性骨髓瘤患者的随机、双盲、安慰剂对照研究中炎症和贫血相关生物标志物的分析。
Clin Cancer Res. 2015 Oct 1;21(19):4294-304. doi: 10.1158/1078-0432.CCR-15-0134. Epub 2015 Jun 29.
5
Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor.单中心 114 例 Castleman 病患者的临床和实验室特征:副肿瘤天疱疮是一个不利的预后因素。
Br J Haematol. 2015 Jun;169(6):834-42. doi: 10.1111/bjh.13378. Epub 2015 Mar 30.
6
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.FDA 批准:西妥昔单抗治疗多中心型 Castleman 病。
Clin Cancer Res. 2015 Mar 1;21(5):950-4. doi: 10.1158/1078-0432.CCR-14-1678. Epub 2015 Jan 19.
7
Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience.人类免疫缺陷病毒阴性的多中心Castleman病患者的临床特征及预后:单中心经验
Blood Res. 2014 Dec;49(4):253-8. doi: 10.5045/br.2014.49.4.253. Epub 2014 Dec 23.
8
Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.利妥昔单抗联合脂质体阿霉素治疗合并卡波西肉瘤相关多中心Castleman病的HIV感染患者。
Blood. 2014 Dec 4;124(24):3544-52. doi: 10.1182/blood-2014-07-586800. Epub 2014 Oct 20.
9
Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease.多中心性Castleman病患者的临床特征及医疗利用情况
Br J Haematol. 2015 Jan;168(1):82-93. doi: 10.1111/bjh.13111. Epub 2014 Sep 11.
10
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.西妥昔单抗治疗多发性 Castleman 病的随机、双盲、安慰剂对照试验。
Lancet Oncol. 2014 Aug;15(9):966-74. doi: 10.1016/S1470-2045(14)70319-5. Epub 2014 Jul 17.